Sign In
Buy BHC
$4.85
+0.0700 (+1.46%)
At Close: Jul 13, 2026
Bausch to stop glaucoma eye drop development after trial miss
05:12pm, Thursday, 09'th Jul 2026
Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
07:00am, Tuesday, 07'th Jul 2026
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Healt
Michael Goettler Resigns from Bausch Health's Board of Directors
04:15pm, Wednesday, 01'st Jul 2026
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in con
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
12:31pm, Friday, 29'th May 2026
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
04:15pm, Thursday, 28'th May 2026
Thermage ® , a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, M
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
04:20pm, Wednesday, 20'th May 2026
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
04:15pm, Tuesday, 19'th May 2026
LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders (
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
03:31pm, Tuesday, 19'th May 2026
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
07:00am, Tuesday, 19'th May 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
07:00am, Wednesday, 13'th May 2026
LAVAL, QC, May 13, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice Preside
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
04:15pm, Tuesday, 12'th May 2026
LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th An
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
07:00am, Thursday, 07'th May 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European l
Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging
06:25am, Thursday, 07'th May 2026
Bausch Health delivered a Q1 revenue and net profit beat, but organic growth remains weak and demand is stagnant. BHC's improved margins stem from reduced rebates and discounts, but underlying sales v
Why Bausch Health Companies Was Crawling Higher This Week
01:09am, Friday, 01'st May 2026
There was notable growth on both the top and bottom lines. The two metrics also topped analyst estimates.
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
11:55am, Thursday, 30'th Apr 2026
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.
